Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

"Conflict of interest Prof. Agewall and Prof. Atar report personal fees from Boehringer Ingelheim (outside the submitted work). Prof. Cleland reports grants and personal fees from Abbott, Amgen, Bayer, Bristol-Myers Squibb, and Torrent Pharmaceuticals; personal fees from AstraZeneca and Myokardia; grants, personal fees and non-financial support from Medtronic, Novartis, and Vifor; grants and non-financial support from Pharmacosmos and PharmaNord (outside the submitted work). Prof. Katus reports personal fees from AstraZeneca, Boehringer Ingelheim, Roche Diagnostics, Bayer Vital, and Daiichi Sankyo (outside the submitted work)."

"Open Access funding provided by Projekt DEAL."

"We performed the present review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for reporting systematic reviews incorporating NMAs of health care interventions [–]. The protocol of the NMA was prospectively registered at final registration ID at PROSPERO: CRD42020151112."